Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of concomitant MCV4, Tdap, and bivalent rLP2086 vaccination in healthy adolescents
2013-002145-11Phase 2
- Sponsor
- Pfizer
- Start
- May 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of meningococcal group B recombinant lipoprotein 2086 vaccine, Meningococcal conjugate vaccine quadrivalent, tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in invasive meningococcal disease (IMD), sponsored by Pfizer.
02
Drugs
meningococcal group B recombinant lipoprotein 2086 vaccineMeningococcal conjugate vaccine quadrivalenttetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
03
Conditions
invasive meningococcal disease (IMD)
Beyond the preview
Go deeper on 2013-002145-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002145-11.